Elliott Jonathan, Oyama Mark A
Department of Comparative Biomedical Sciences, Royal Veterinary College, University of London, London, UK.
Department of Clinical Sciences & Advanced Medicine, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania, USA.
J Vet Pharmacol Ther. 2025 Jan;48 Suppl 1(Suppl 1):1-18. doi: 10.1111/jvp.13472. Epub 2024 Jul 13.
Sodium glucose transporter type 2 (SGLT2) inhibitors have been introduced into human medicine where their beneficial effects go beyond the expected improvement in blood glucose control. These drugs appear to prevent progression of both cardiovascular and kidney diseases, not only in diabetic but also in non-diabetic human patients. As these drugs have received conditional approval for use in diabetic cats and are being used in other veterinary species, the intriguing question as to whether they will have similar cardioprotective and nephroprotective effects in dogs and cats is being asked. The primary mechanism(s) by which SGLT2 inhibitors are cardio- and nephroprotective remain to be fully characterized. This paper reviews these suggested mechanisms in the context of the pathophysiology of progressive cardiovascular and kidney diseases in dogs and cats with the goal of predicting which categories of non-diabetic veterinary patients these drugs might be of most benefit.
钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂已被应用于人类医学，其有益作用超出了预期的血糖控制改善效果。这些药物似乎不仅能预防糖尿病患者，还能预防非糖尿病患者的心血管疾病和肾脏疾病进展。由于这些药物已获得有条件批准用于糖尿病猫，并且正在其他兽医物种中使用，因此人们提出了一个有趣的问题，即它们在犬猫中是否会有类似的心脏保护和肾脏保护作用。SGLT2抑制剂发挥心脏和肾脏保护作用的主要机制仍有待充分阐明。本文在犬猫进行性心血管和肾脏疾病病理生理学的背景下，综述了这些推测的机制，目的是预测这些药物可能对哪些类别的非糖尿病兽医患者最有益。
